{"id":"mk-3415a","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":{"chemblId":"CHEMBL2057618","moleculeType":"Small molecule","molecularWeight":"164.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OX40 is an inducible T-cell costimulatory molecule that plays a key role in T-cell proliferation and survival. By blocking OX40 signaling, MK-3415A enhances T-cell-mediated immune responses against cancer cells. This approach aims to overcome immune suppression in the tumor microenvironment and improve anti-tumor efficacy, often in combination with other immunotherapies.","oneSentence":"MK-3415A is a monoclonal antibody that targets and inhibits OX40, a costimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:34.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT01241552","phase":"PHASE3","title":"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-10","conditions":"Clostridium Difficile Infection","enrollment":1452},{"nctId":"NCT01513239","phase":"PHASE3","title":"A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-01","conditions":"Clostridium Difficile Infection","enrollment":1203}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK-3415A","genericName":"MK-3415A","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"MK-3415A is a monoclonal antibody that targets and inhibits OX40, a costimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}